Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Constitutive NF-κB signaling is central to chronic inflammation and autoimmune conditions.
• TNF receptor-associated factor 6 (TRAF6) is a critical E3 ligase linking innate immunity and antigen receptors to NF-κB.
• TRAF6's interaction with Ubc13 is essential for generating Lys63-linked ubiquitin chains that propagate inflammatory signals.

Purpose of the Study:

• To discover and characterize a small molecule inhibitor of the TRAF6-Ubc13 interaction.
• To evaluate the compound's efficacy in inhibiting NF-κB signaling in cellular and preclinical models.
• To explore a novel therapeutic strategy for autoimmune and chronic inflammatory diseases by targeting TRAF6.

Main Methods:

• High-throughput small-molecule screening to identify TRAF6-Ubc13 inhibitors.
• In vitro and cellular assays to assess compound activity on TRAF6-Ubc13 interaction and NF-κB activation.
• Preclinical in vivo studies in mouse models of psoriasis and rheumatoid arthritis to evaluate therapeutic potential.

Main Results:

• Discovery of C25-140, a potent inhibitor of the TRAF6-Ubc13 interaction.
• C25-140 effectively reduced NF-κB activation in various immune and inflammatory pathways in human and murine cells.
• Administration of C25-140 ameliorated inflammation and improved disease outcomes in mouse models of psoriasis and rheumatoid arthritis.

Conclusions:

• The first-in-class TRAF6-Ubc13 inhibitor, C25-140, provides a valuable tool for studying ubiquitin signaling in immunity.
• Targeting TRAF6 E3 ligase activity with small molecules is a promising therapeutic approach for autoimmune diseases like psoriasis and rheumatoid arthritis.
• Inhibition of the TRAF6-Ubc13 interaction represents a novel strategy for managing chronic inflammatory conditions.